Hormonal
Caloric restriction extends lifespan and promotes longevity by inducing dramatic changes in mitochondrial protein acetylation, thereby enhancing mitochondrial adaptation to reduced caloric intake.
Caloric restriction is a proven method to extend lifespan in various species by altering how mitochondria function. This happens through changes in protein acetylation, which helps cells adapt to lower energy availability. While strict restriction is hard to maintain, the underlying mechanism suggests that managing energy intake to avoid overfeeding may support healthy aging processes.
Most notably, it has been found that caloric restriction (CR), an intervention known to extend the lifespan in many organisms ranging from budding yeast to mammals, is associated with dramatic changes in mitochondrial acetylation. Many proteins are altered by acetylation in response to CR [119, 120]. These changes may contribute to mitochondrial adaptation to reduced caloric intake and may help to promote longevity.
Why this rating
This is a review article summarizing evidence from various model organisms (yeast to mammals), not a single clinical trial.
Source
Protein Posttranslational Modifications: Roles in Aging and Age‐Related Disease
Ana L. Santos et al. · Oxidative Medicine and Cellular Longevity · 2017
DOI 10.1155/2017/5716409
More from this paper
- Loss of proteostasis, characterized by the accumulation of abnormal proteins due to decreased cellular capacity to degrade them, is a hallmark of aging and contributes to age-related pathologies like neurodegenerative diseases.Good
- Regular exercise reduces oxidatively modified proteins in the brain and improves cognitive function through PTM processes involving histone regulation.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →